InflaRx CEO Dr. Niels Riedmann joins Rx for Biotech to discuss how the company is pioneering complement-directed therapies to control severe inflammation and autoimmune disease. We break down the science behind INF904, and why C5a is such a powerful immune driver, and how precision immunology is shaping the next wave of treatment innovation.
